Seattle Genetics Inc. (SGEN) Adcetris Gets FDA Approval

Thank you for joining us. I am your host Yohemy Auerbach at CRWE Newswire Stocks to watch. Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings. Lymphoma is a general term for a group of cancers that originate in the lymphatic system. According to the National Cancer Institute, Estimated 8,830 new cases and 1,300 deaths from Hodgkin lymphoma in the United States in 2011. Seattle Genetics has U.S. and Canadian commercialization rights for adcetris. The company expects to make ADCETRIS available to patients in the next week. Thank you for tuning in, have a great day. For CRWE Newswire, Stocks to watch, I’m Yohemy Auerbach.

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

1. By: karmastock
2. Categories News & Events
3. Views 7
4. Added :20-Aug-11
   Report This Video